Table 1.
Patient characteristics
| Age (y) |
Median (range) |
71 (50–83) |
||
|---|---|---|---|---|
| N | % | |||
| T stage |
T1 |
|
34 |
24 |
| |
T2 |
|
40 |
28 |
| |
T3 |
|
67 |
48 |
| Gleason score |
<8 |
|
73 |
52 |
| |
8 − 10 |
|
68 |
48 |
| Initial PSA |
≤20 |
|
93 |
66 |
| |
>20 |
|
48 |
34 |
| NCCN riskGroup |
IR |
|
36 |
26 |
| |
HR |
|
105 |
74 |
| ADT |
|
Yes |
124 |
88 |
| |
|
IR |
24 |
17 |
| |
|
HR |
100 |
71 |
| |
|
STADT |
27 |
22 |
| |
|
LTADT |
97 |
78 |
| |
|
No |
17 |
12 |
| Diabetes |
|
|
23 |
16 |
| Hypertension |
|
|
50 |
35 |
| Hemorrhoid | 37 | 26 |
Abbreviations: PSA, prostate-specific antigen; NCCN, national comprehensive cancer network; IR, intermediate risk; HR, high risk; ADT, androgen-deprivation therapy; STADT, short-term ADT; LTADT, long-term ADT.